News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cellomics, Inc. And Becton, Dickinson And Company (BDX) Sign License Agreement To Further Expand Availability Of High Content Screening


10/19/2005 5:12:08 PM

PITTSBURGH and SAN JOSE, Calif., Nov. 9 /PRNewswire/ -- Cellomics, Inc., the creator of High Content Screening (HCS), and global medical technology company BD (Becton, Dickinson and Company), through its BD Biosciences unit, announced today that they have entered into a non-exclusive, worldwide patent license agreement. The agreement will provide BD with Cellomics' core High Content Screening patent portfolio that includes both broad claims to HCS technology and specific classes of HCS assays such as cytoplasm-nuclear translocation, characterization of cellular toxicity, and receptor internalization. Financial details of the agreement were not disclosed.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010611/PHM032LOGO )

"We are very pleased to be working with BD to further expand the adoption and availability of high content screening technology. Through the licensing of our HCS patent portfolio, we are seeking to enable customers to more effectively address complex biological questions," commented William T. Sharp, Cellomics' Vice President of Business Development.

"With the recent acquisition of Atto Biosciences, and our licensing of this intellectual property from Cellomics, BD Biosciences extends our commitment to the area of high-content cellular analysis and strengthens our considerable capabilities in the area of live cell research that includes high-resolution imaging, flow cytometry and a broad array of reagent systems," added Mark Lewis, Vice President of BD Biosciences.

"Completion of this second significant licensing arrangement of our HCS patent portfolio with a global company like BD confirms the value of our extensive intellectual property in this critical area of drug discovery and reaffirms our intent to facilitate the expansion of the HCS market via an aggressive licensing and commercial strategy," stated Daniel J. Calvo, Cellomics' President and CEO.

About BD

BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry, and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. For the fiscal year ended September 30, 2004, BD reported revenues of $4.935 billion.

About BD Biosciences

A business segment of BD, BD Biosciences ( http://www.bdbiosciences.com/ ) is one of the world's largest businesses supporting the life sciences and is organized into four units: Clontech, Discovery Labware, Immunocytometry Systems, and Pharmingen. BD Biosciences provides high-quality products and services to accelerate discovery and diagnosis in the life sciences.

About Cellomics

Cellomics, Inc. is automating drug discovery through a unique, cell-based assay platform that addresses the needs of Drug Discovery and Systems Biology groups by offering complete systems for High Content Screening. Cellomics' proprietary HCSinstruments, software, and assays are in use worldwide in pharmaceutical, biotechnology, and academic institutions.

For further information, contact: Cellomics: Judy P. Masucci, Ph.D. Director of Marketing Cellomics, Inc. 100 Technology Drive Pittsburgh, PA 15219 412-770-2200 x 2353 412-770-2450 (fax) pr@cellomics.com BD: Colleen T. White, Corporate Communications 201-847-5369 colleen_white@bd.com Phil Vanek Director of Marketing 301-340-7320 x 226 pvanek@atto.com

This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; and changes in healthcare or other governmental regulation; issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

Photo: http://www.newscom.com/cgi-bin/prnh/20010611/PHM032LOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.comCellomics, Inc.

CONTACT: Judy P. Masucci, Ph.D., Director of Marketing of Cellomics,Inc., +1-412-770-2200, ext. 2353, or fax, +1-412-770-2450, orpr@cellomics.com ; or Colleen T. White, Corporate Communications,+1-201-847-5369, or colleen_white@bd.com , or Phil Vanek, Director ofMarketing, +1-301-340-7320, ext. 226, or pvanek@atto.com , both of BD


Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES